Sellebjerg F - Search Results

1

Treatment Escalation vs Immediate Initiation of Highly Effective Treatment for Patients With Relapsing-Remitting Multiple Sclerosis: Data From 2 Different National Strategies.

Spelman T, Magyari M, Piehl F, Svenningsson A, Rasmussen PV, Kant M, Sellebjerg F, Joensen H, Hillert J, Lycke J. Spelman T, et al. Among authors: sellebjerg f. JAMA Neurol. 2021 Oct 1;78(10):1197-1204. doi: 10.1001/jamaneurol.2021.2738. JAMA Neurol. 2021. PMID: 34398221 Free PMC article.

2

Double-blind, randomized, placebo-controlled study of oral, high-dose methylprednisolone in attacks of MS.

Sellebjerg F, Frederiksen JL, Nielsen PM, Olesen J. Sellebjerg F, et al. Neurology. 1998 Aug;51(2):529-34. doi: 10.1212/wnl.51.2.529. Neurology. 1998. PMID: 9710030 Clinical Trial.

3

Increased T cell expression of CD154 (CD40-ligand) in multiple sclerosis.

Jensen J, Krakauer M, Sellebjerg F. Jensen J, et al. Among authors: sellebjerg f. Eur J Neurol. 2001 Jul;8(4):321-8. doi: 10.1046/j.1468-1331.2001.00232.x. Eur J Neurol. 2001. PMID: 11422428

4

Distinct chemokine receptor and cytokine expression profile in secondary progressive MS.

Sørensen TL, Sellebjerg F. Sørensen TL, et al. Among authors: sellebjerg f. Neurology. 2001 Oct 23;57(8):1371-6. doi: 10.1212/wnl.57.8.1371. Neurology. 2001. PMID: 11673573

5

IV immunoglobulins as add-on treatment to methylprednisolone for acute relapses in MS.

Sorensen PS, Haas J, Sellebjerg F, Olsson T, Ravnborg M; TARIMS Study Group. Sorensen PS, et al. Among authors: sellebjerg f. Neurology. 2004 Dec 14;63(11):2028-33. doi: 10.1212/01.wnl.0000145798.61383.39. Neurology. 2004. PMID: 15596745 Clinical Trial.

6

EFNS guideline on treatment of multiple sclerosis relapses: report of an EFNS task force on treatment of multiple sclerosis relapses.

Sellebjerg F, Barnes D, Filippini G, Midgard R, Montalban X, Rieckmann P, Selmaj K, Visser LH, Sørensen PS; EFNS Task Force on Treatment of Multiple Sclerosis Relapses. Sellebjerg F, et al. Eur J Neurol. 2005 Dec;12(12):939-46. doi: 10.1111/j.1468-1331.2005.01352.x. Eur J Neurol. 2005. PMID: 16324087

7

Neutralising antibodies to interferon beta in multiple sclerosis : expert panel report.

Hartung HP, Polman C, Bertolotto A, Deisenhammer F, Giovannoni G, Havrdova E, Hemmer B, Hillert J, Kappos L, Kieseier B, Killestein J, Malcus C, Comabella M, Pachner A, Schellekens H, Sellebjerg F, Selmaj K, Sorensen PS. Hartung HP, et al. Among authors: sellebjerg f. J Neurol. 2007 Jul;254(7):827-37. doi: 10.1007/s00415-006-0486-3. Epub 2007 Apr 24. J Neurol. 2007. PMID: 17457510 Review.

8

Gene expression analysis of interferon-beta treatment in multiple sclerosis.

Sellebjerg F, Datta P, Larsen J, Rieneck K, Alsing I, Oturai A, Svejgaard A, Soelberg Sørensen P, Ryder LP. Sellebjerg F, et al. Mult Scler. 2008 Jun;14(5):615-21. doi: 10.1177/1352458507085976. Epub 2008 Apr 11. Mult Scler. 2008. PMID: 18408020 Clinical Trial.

9

Increased IL-10 mRNA and IL-23 mRNA expression in multiple sclerosis: interferon-beta treatment increases IL-10 mRNA expression while reducing IL-23 mRNA expression.

Krakauer M, Sorensen P, Khademi M, Olsson T, Sellebjerg F. Krakauer M, et al. Among authors: sellebjerg f. Mult Scler. 2008 Jun;14(5):622-30. doi: 10.1177/1352458507087136. Epub 2008 Apr 18. Mult Scler. 2008. PMID: 18424480 Clinical Trial.

10

Refining genetic associations in multiple sclerosis.

International Multiple Sclerosis Genetics Consortium (IMSGC). International Multiple Sclerosis Genetics Consortium (IMSGC). Lancet Neurol. 2008 Jul;7(7):567-9. doi: 10.1016/S1474-4422(08)70122-4. Lancet Neurol. 2008. PMID: 18565446 Free PMC article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

321 results

Search Page